Memorial Hospital Research Laboratories
The Lee Jones Lab
Exercise Oncology Service
Our research group studies the utility of different methods to characterize the chronic and long-term adverse cardiovascular side effects of conventional and novel cancer therapies. By investigating the use of these tools, we can better understand how cancer therapeutics damage organs such as the heart and skeletal muscles, as well as identify those individuals at high risk of cardiovascular side effects. In doing so, we can design therapeutic interventions to prevent and/or mitigate these devastating side effects.
Jones LW, Habel LA, Weltzien E, Castillo A, Gupta D, Kroenke CH, Kwan ML, Queensberry CP, Scott J, Sternfeld B, Yu, A, Kushi LH, Caan BJ. Exercise and prognosis on the basis of clinicopathologic and molecular features in early stage breast cancer: The LACE and Pathways studies. Cancer Res. 2016 Aug 3.
Jones LW, Habel LA, Weltzien E, Castillo A, Gupta D, Kroenke CH, Kwan ML, Queensberry CP, Scott J, Sternfeld B, Yu, A, Kushi LH, Caan BJ. Exercise and risk of cardiovascular events in women with non-metastatic breast cancer. J Clin Oncol. 2016 May.
Jones LW, Liu Q, Armstrong GT, Ness KK, Yasui Y, Devine K, Tonorezos E, Soares-Miranda L, Sklar CA, Douglas PS, Robison LL, Oeffinger KC. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study. Journal of Clinical Oncology. 2014, 32:3643-50.
Betof AS, Lascola CD, Fowler E, Scarbrough PM, Jones LW*, Dewhirst MW*. Exercise inhibits tumor progression and sensitizes tumors to chemotherapy in orthotoptic models of breast cancer. Journal of the National Cancer Institute. In Press *co-senior authorship.
Lee Jones, PhD
- Exercise scientist Lee Jones focuses on the efficacy and mechanisms of exercise training on cardiovascular toxicities and tumor initiation and progression.
- [email protected]
- Email Address
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Lee Jones discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.